Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
exenatide extended-release
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- Small Molecules, Peptides
- Administration
- Subcutaneous
01
Overview
Bydureon is an extended-release formulation of exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes mellitus. It works by enhancing glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriately elevated glucagon secretion, and slowing gastric emptying. The medication is formulated using biodegradable microsphere technology that allows for once-weekly dosing. The microspheres are composed of polylactide co-glycolide acid polymer that gradually degrades, releasing exenatide continuously over time.
- Brand names
- BydureonBydureon BCise
- Other names
- exenatide extended-release for injectable suspensionexenatide once-weekly suspensionReady to Use Exenatide Once Weekly
02
Targets
Beyond the preview
Go deeper on exenatide extended-release.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on exenatide extended-release.